The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat

被引:69
作者
Natesan, Sridhar
Svensson, Kjell A.
Reckless, Greg E.
Nobrega, Jose N.
Barlow, Karen B. L.
Johansson, Anette M.
Kapur, Shitij
机构
[1] Ctr Addict & Mental Hlth, Schizophrenia Program, Toronto, ON M5S 2S1, Canada
[2] Ctr Addict & Mental Hlth, PET Ctr, Toronto, ON M5S 2S1, Canada
[3] Ctr Addict & Mental Hlth, Neuroimaging Res Sect, Toronto, ON M5S 2S1, Canada
[4] Lilly Res Labs, Indianapolis, IN USA
[5] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[6] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
关键词
D O I
10.1124/jpet.106.102905
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dopamine stabilizers are a new class of compounds that have the ability to reverse both hypo- as well as hyperdopaminergia in vivo. This class, exemplified by the phenylpiperidines (S)-(-)-3-(3-methanesulfonyl- phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl)-piperidine [ACR16] although lacking high in vitro binding affinity for dopamine D-2 receptor [(-)-OSU6162, K-i = 447 nM; ACR16, K-i > 1 mu M], shows functional actions, suggestive of their interaction. Hence, we evaluated in vivo D-2 occupancy of these agents in rats and correlated it to observed effects in a series of behavioral, neurochemical, and endocrine models relevant to the dopamine system and antipsychotic effect. Both (-)-OSU6162 and ACR16 showed robust dose- dependent striatal D-2 occupancy with ED50 values of 5.27 and 18.99 mg/kg s.c., respectively, and functional assays showed no partial agonism. Over an occupancy range of 37 to 87% (3-60 mg/kg) for (-)-OSU6162 and 35 to 74% (10-60 mg/kg) for ACR16, we observed both inhibitory (amphetamine-induced locomotor activity) and stimulatory effects (in habituated rats). Haloperidol, over a similar occupancy range (33-78%), potently inhibited psychostimulant activity and induced catalepsy, but it failed to activate habituated animals. In the conditioned avoidance response assay, ACR16 was clearly more efficacious than (-)OSU6162. In addition, both these compounds demonstrated significant preferential Fos induction in the nucleus accumbens compared with the dorsolateral striatum, a strong predictor of atypical antipsychotic efficacy. The results suggest that dopamine stabilizers exhibit locomotor stabilizing as well as antipsychoticlike effects, with low motor side effect liability, in a dose range that corresponds to high D-2 in vivo occupancy.
引用
收藏
页码:810 / 818
页数:9
相关论文
共 40 条
[21]   PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's Disease [J].
Nichols, NF ;
Cimini, MG ;
Haas, JV ;
Staton, BA ;
Tedroff, J ;
Svensson, KA .
NEUROPHARMACOLOGY, 2002, 43 (05) :817-824
[22]   Dopamine: a key regulator to adapt action, emotion, motivation and cognition [J].
Nieoullon, A ;
Coquerel, A .
CURRENT OPINION IN NEUROLOGY, 2003, 16 :S3-S9
[23]   The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition [J].
Nilsson, M ;
Carlsson, A ;
Markinhuhta, KR ;
Sonesson, C ;
Pettersson, F ;
Gullme, M ;
Carlsson, ML .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (04) :677-685
[24]   Novel antipsychotic agents with dopamine autoreceptor agonist properties:: Synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives [J].
Oshiro, Y ;
Sato, S ;
Kurahashi, N ;
Tanaka, T ;
Kikuchi, T ;
Tottori, K ;
Uwahodo, Y ;
Nishi, T .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (05) :658-667
[25]  
PETTERSON F, 2002, DEV ACR16
[26]  
ROBERTSON GS, 1994, J PHARMACOL EXP THER, V271, P1058
[27]   The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats [J].
Rung, JP ;
Carlsson, A ;
Markinhuhta, KR ;
Carlsson, ML .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2005, 29 (05) :833-839
[28]   DOPAMINE-RECEPTORS AND THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA [J].
SEEMAN, P .
SYNAPSE, 1987, 1 (02) :133-152
[29]   BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF OPC-14597, A NOVEL ANTIPSYCHOTIC DRUG, ON DOPAMINERGIC MECHANISMS IN RAT-BRAIN [J].
SEMBA, J ;
WATANABE, A ;
KITO, S ;
TORU, M .
NEUROPHARMACOLOGY, 1995, 34 (07) :785-791
[30]   SUBSTITUTED (S)-PHENYLPIPERIDINES AND RIGID CONGENERS AS PREFERENTIAL DOPAMINE AUTORECEPTOR ANTAGONISTS - SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS [J].
SONESSON, C ;
LIN, CH ;
HANSSON, L ;
WATERS, N ;
SVENSSON, K ;
CARLSSON, A ;
SMITH, MW ;
WIKSTROM, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (17) :2735-2753